PYC Therapeutics (ASX:PYC) said it had cash and treasury investments of AU$655 million at Sept. 30, according to a Thursday Australian bourse filing.
The company said it has three investigational drug candidates with disease-modifying potential in clinical development, with a fourth expected to enter human trials in 2027.
The company's third-quarter progress included its polycystic kidney disease program and its Phelan-McDermid syndrome program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments